• Mon news: AZ obesity pill. 50% of drug shortages last at least 2 years. Pharmas and IRA lawsuit appeals. Novo-Ascendis biobucks deal. Wegovy reduces all-cause hospital admissions. See more on our front page

diabetes

  1. Wonka

    The gentleman in “Get Real” commercial

    I like the guy and like the commercial, but is that same guy in a Smirnoff commercial right now. Looks like same guy, but maybe not. If it is, probably not a good thing. Poor due diligence.
  2. Eli Lilly Diabetes Contract

    Anyone else on the Jardiance contract? First day was today, what are your thoughts so far? Seems like a massive team. first time with Syneos, trying to get discussion started with some more experienced reps on what to expect.
  3. Novo Nordisk reports first quarter results

    Novo Nordisk says pricing pressure within diabetes to continue, especially in the US. First quarter 2019 results: Sales from North America Operations declined 4% on constant exchange rates.
  4. Off Label Promotion

    I think reps in my district are being asked to promote a drug off label. Not quite sure what to do, Anyone else with that issue?
  5. Upbeat performance in Q4

    Medtronic posted better-than-expected fourth quarter earnings. Earnings came in at $1.07 a share. Excluding items, the company earned $1.42, topping analysts’ estimate of $1.39. Revenue came in at $8.1 billion, meeting the consensus estimate of $8 billion. Strong global demand for the new...
  6. Is Afrezza even that great?

    Seems like most who try it never refill it. Horrible retention numbers. Makes me believe the product isn’t as great as the shills on message boards/twitter make it out to be.
  7. Lilly sees pressure on pricing across all diabetes products

    Eli Lilly reports an increase in pharma sales and decline in Animal Health. Lifts 2018 earnings outlook. When answering an analyst question, Enrique Conterno said, "We continue to see pressure on pricing across all of our diabetes products".
  8. Celgene's future seems to be a big question mark

    http://alphastreet.com/b0662389 Celgene's outlook, especially it's long-term targets, is not an encouraging one. Also, a decrease in pharma company's research and development expenses is not a good sign.
  9. Dave Ricks hopes for a favorable tax reform

    Lilly expects to continue the investments in U.S., if favorable tax reform measures are enacted. Announces a $72 million investment in an insulin manufacturing project. http://alphastreet.com/b3264790
  10. Lilly helps Puerto Rico

    Lilly to help the people of Puerto Rico to recover from the destruction of Hurricane Maria,
  11. Diabetes - Lilly's competition with Sanofi

    Lilly's Humalog Junior KwikPen will be available now in U.S. Lilly KwikPen vs. Sanofi Solostar. Which insulin pen is going to win the race?
  12. Diabetes - Lilly's competition with Novo Nordisk

    Lilly's Humalog Junior KwikPen will be available now in U.S. Lilly KwikPen vs. Novo Nordisk FlexPen. Which insulin pen is going to win the race?
  13. Diabetes - Lilly's competition with Sanofi and Novo Nordisk

    Lilly's Humalog Junior KwikPen will be available now in U.S. Lilly KwikPen vs. Novo Nordisk FlexPen vs. Sanofi Solostar. Which insulin pen is going to win the race?
  14. Boehringer Ingelheim and Eli Lilly collaboration

    Approximately 30 million Americans have diabetes, and nearly 24 percent of Americans with diabetes are undiagnosed. This partnership will create a model that predicts complications from type 2 diabetes
  15. What division in Medtronic is the least stressful?

    Internet trolls, please stay away. I'm looking for an honest answer. I've been with Medtronic for a year and don't like my division (won't specify). The hours are grueling, I'm constantly go go go. I just want somewhat of a less stressful position, but I like working for the company. What...